基于结构的 G 蛋白偶联受体药物筛选。
Structure-based drug screening for G-protein-coupled receptors.
机构信息
Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
出版信息
Trends Pharmacol Sci. 2012 May;33(5):268-72. doi: 10.1016/j.tips.2012.03.007. Epub 2012 Apr 13.
Abstract
G-protein-coupled receptors (GPCRs) represent a large family of signaling proteins that includes many therapeutic targets; however, progress in identifying new small molecule drugs has been disappointing. The past 4 years have seen remarkable progress in the structural biology of GPCRs, raising the possibility of applying structure-based approaches to GPCR drug discovery efforts. Of the various structure-based approaches that have been applied to soluble protein targets, such as proteases and kinases, in silico docking is among the most ready applicable to GPCRs. Early studies suggest that GPCR binding pockets are well suited to docking, and docking screens have identified potent and novel compounds for these targets. This review will focus on the current state of in silico docking for GPCRs.
摘要
G 蛋白偶联受体（GPCRs）是一大类信号蛋白家族，其中包括许多治疗靶点；然而，在发现新的小分子药物方面的进展却令人失望。在过去的 4 年中，GPCR 的结构生物学取得了显著进展，为应用基于结构的方法进行 GPCR 药物发现提供了可能。在已经应用于可溶性蛋白靶标的各种基于结构的方法中，如蛋白酶和激酶，计算对接是最适合 GPCR 的方法之一。早期研究表明，GPCR 结合口袋非常适合对接，对接筛选已经为这些靶点鉴定了有效和新颖的化合物。本文将重点介绍目前用于 GPCR 的计算对接技术。
相似文献
1
Structure-based drug screening for G-protein-coupled receptors.基于结构的 G 蛋白偶联受体药物筛选。
Trends Pharmacol Sci. 2012 May;33(5):268-72. doi: 10.1016/j.tips.2012.03.007. Epub 2012 Apr 13.
2
Importance of protein dynamics in the structure-based drug discovery of class A G protein-coupled receptors (GPCRs).在基于结构的 A 类 G 蛋白偶联受体（GPCRs）药物发现中，蛋白质动力学的重要性。
Curr Opin Struct Biol. 2019 Apr;55:147-153. doi: 10.1016/j.sbi.2019.03.015. Epub 2019 May 16.
3
Structure-based and fragment-based GPCR drug discovery.基于结构和基于片段的G蛋白偶联受体药物发现
ChemMedChem. 2014 Feb;9(2):256-75. doi: 10.1002/cmdc.201300382. Epub 2013 Dec 18.
4
Fragment-based lead discovery on G-protein-coupled receptors.基于片段的 G 蛋白偶联受体的先导化合物发现。
Expert Opin Drug Discov. 2013 Jul;8(7):811-20. doi: 10.1517/17460441.2013.794135. Epub 2013 Apr 29.
5
Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures.通过分子对接筛选发现 G 蛋白偶联受体配体：晶体结构提供的新机遇。
Curr Top Med Chem. 2015;15(24):2484-503. doi: 10.2174/1568026615666150701112853.
6
Efficiency of Homology Modeling Assisted Molecular Docking in G-protein Coupled Receptors.同源建模辅助分子对接在 G 蛋白偶联受体中的效率。
Curr Top Med Chem. 2021;21(4):269-294. doi: 10.2174/1568026620666200908165250.
7
From purified GPCRs to drug discovery: the promise of protein-based methodologies.从纯化的G蛋白偶联受体到药物发现：基于蛋白质方法的前景。
Curr Opin Pharmacol. 2009 Oct;9(5):629-35. doi: 10.1016/j.coph.2009.04.002. Epub 2009 May 13.
8
The year in G protein-coupled receptor research.G蛋白偶联受体研究进展之年。
Mol Endocrinol. 2010 Jan;24(1):261-74. doi: 10.1210/me.2009-0473. Epub 2009 Dec 17.
9
The impact of GPCR structures on pharmacology and structure-based drug design.G 蛋白偶联受体结构对药理学和基于结构的药物设计的影响。
Br J Pharmacol. 2010 Mar;159(5):986-96. doi: 10.1111/j.1476-5381.2009.00476.x. Epub 2009 Nov 13.
10
Virtual Screening of Human Class-A GPCRs Using Ligand Profiles Built on Multiple Ligand-Receptor Interactions.基于多种配体-受体相互作用构建配体特征对人 A 类 GPCR 的虚拟筛选
J Mol Biol. 2020 Aug 7;432(17):4872-4890. doi: 10.1016/j.jmb.2020.07.003. Epub 2020 Jul 9.
引用本文的文献
1
From Concepts to Inhibitors: A Blueprint for Targeting Protein-Protein Interactions.从概念到抑制剂：靶向蛋白质-蛋白质相互作用的蓝图
Chem Rev. 2025 Jul 23;125(14):6819-6869. doi: 10.1021/acs.chemrev.5c00046. Epub 2025 Jun 24.
2
GPR43 regulates mitochondrial apoptosis through the cyclophilin D pathway in Alzheimer's disease.GPR43通过亲环素D途径调节阿尔茨海默病中的线粒体凋亡。
Mol Med. 2025 Jun 4;31(1):219. doi: 10.1186/s10020-025-01269-4.
3
Systems Biology-Driven Discovery of Host-Targeted Therapeutics for Oropouche Virus: Integrating Network Pharmacology, Molecular Docking, and Drug Repurposing.系统生物学驱动的奥罗普切病毒宿主靶向治疗药物发现：整合网络药理学、分子对接和药物再利用
Pharmaceuticals (Basel). 2025 Apr 23;18(5):613. doi: 10.3390/ph18050613.
4
G Protein-Coupled Receptors: A Century of Research and Discovery.G 蛋白偶联受体：一个世纪的研究与发现。
Circ Res. 2024 Jun 21;135(1):174-197. doi: 10.1161/CIRCRESAHA.124.323067. Epub 2024 Jun 20.
5
Carbenoid-involved reactions integrated with scaffold-based screening generates a Nav1.7 inhibitor.与基于骨架的筛选相结合的卡宾参与反应生成了一种Nav1.7抑制剂。
Commun Chem. 2024 Jun 12;7(1):135. doi: 10.1038/s42004-024-01213-3.
6
Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5.拮抗剂与趋化因子受体CCR2和CCR5相互作用的分子决定因素
bioRxiv. 2024 Feb 12:2023.11.15.567150. doi: 10.1101/2023.11.15.567150.
7
Differential Expression of Proteins Associated with Bipolar Disorder as Identified Using the PeptideShaker Software.使用 PeptideShaker 软件鉴定出与双相情感障碍相关的差异表达蛋白。
Int J Mol Sci. 2023 Oct 17;24(20):15250. doi: 10.3390/ijms242015250.
8
Discovery of Potent and Selective CB2 Agonists Utilizing a Function-Based Computational Screening Protocol.利用基于功能的计算筛选方案发现有效且选择性的 CB2 激动剂。
ACS Chem Neurosci. 2023 Nov 1;14(21):3941-3958. doi: 10.1021/acschemneuro.3c00580. Epub 2023 Oct 12.
9
Targeting SLC transporters: small molecules as modulators and therapeutic opportunities.靶向 SLC 转运体：小分子作为调节剂和治疗机会。
Trends Biochem Sci. 2023 Sep;48(9):801-814. doi: 10.1016/j.tibs.2023.05.011. Epub 2023 Jun 22.
10
Detecting and measuring of GPCR signaling - comparison of human induced pluripotent stem cells and immortal cell lines.检测和测量 GPCR 信号——人诱导多能干细胞与永生化细胞系的比较。
Front Endocrinol (Lausanne). 2023 May 24;14:1179600. doi: 10.3389/fendo.2023.1179600. eCollection 2023.
本文引用的文献
1
Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.μ-阿片受体与吗啡喃拮抗剂结合的晶体结构
Nature. 2012 Mar 21;485(7398):321-6. doi: 10.1038/nature10954.
2
Structure and dynamics of the M3 muscarinic acetylcholine receptor.M3 毒蕈碱型乙酰胆碱受体的结构与动力学。
Nature. 2012 Feb 22;482(7386):552-6. doi: 10.1038/nature10867.
3
Crystal structure of a lipid G protein-coupled receptor.脂质 G 蛋白偶联受体的晶体结构。
Science. 2012 Feb 17;335(6070):851-5. doi: 10.1126/science.1215904.
4
Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist.人源 M2 毒蕈碱型乙酰胆碱受体与拮抗剂结合的结构。
Nature. 2012 Jan 25;482(7386):547-51. doi: 10.1038/nature10753.
5
A decade of change.十年的变迁。
Nat Rev Drug Discov. 2012 Jan 3;11(1):17-8. doi: 10.1038/nrd3630.
6
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.基于晶体结构的人源组胺 H（1）受体配体的类片段虚拟筛选。
J Med Chem. 2011 Dec 8;54(23):8195-206. doi: 10.1021/jm2011589. Epub 2011 Nov 7.
7
Ligand discovery from a dopamine D3 receptor homology model and crystal structure.从多巴胺 D3 受体同源模型和晶体结构中发现配体。
Nat Chem Biol. 2011 Sep 18;7(11):769-78. doi: 10.1038/nchembio.662.
8
The use of GPCR structures in drug design.G蛋白偶联受体（GPCR）结构在药物设计中的应用。
Adv Pharmacol. 2011;62:1-36. doi: 10.1016/B978-0-12-385952-5.00011-7.
9
Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment.通过 2010 年 GPCR 对接评估反映的 GPCR 建模和对接的现状。
Structure. 2011 Aug 10;19(8):1108-26. doi: 10.1016/j.str.2011.05.012.
10
Crystal structure of the β2 adrenergic receptor-Gs protein complex.β2 肾上腺素能受体-Gs 蛋白复合物的晶体结构。
Nature. 2011 Jul 19;477(7366):549-55. doi: 10.1038/nature10361.
Zotero 插件